Oral Anaerobic Bacteria in the Etiology of Ankylosing Spondylitis

Mesut Öğrendik

Department of Physical Medicine and Rehabilitation, Uzunköprü State Hospital, Edirne, Turkey.

ABSTRACT: Ankylosing spondylitis (AS) is associated with periodontitis. Anti–Porphyromonas gingivalis and anti–Prevotella intermedia antibody titers were higher in patients with spondyloarthritides than in healthy people. Sulfasalazine is an effective antibiotic treatment for AS. Moxifloxacin and rifamycin were also found to be significantly effective. The etiology hypothesis suggests that oral anaerobic bacteria such as Porphyromonas genus and Prevotella spp contribute to the disease. These bacteria have been identified in AS, and we will discuss their pathogenic properties with respect to our knowledge of the disease. Periodontal pathogens are likely to be responsible for the development of AS in genetically susceptible individuals. This finding should guide the development of more comprehensive and efficacious treatment strategies for AS.

KEYWORDS: Ankylosing spondylitis, oral bacteria, etiology

Introduction

The term periodontal disease (PD) embraces a number of conditions in which the supporting tissues of the teeth are attached.1 Chronic adult periodontitis is the most common form of advanced PD affecting the general population, and it is a major cause of tooth loss after the age of 25 years.1

Ankylosing spondylitis (AS) and other HLA-B27–associated forms of arthritis (eg, reactive arthritis) constitute a relatively common group of arthritides (spondyloarthropathies), affecting up to 2% of White individuals.2 Epidemiologic and familial data have established a strong disease association with the HLA class I antigen B27, but they also suggest that additional genes modify both susceptibility to AS and the phenotypic expression of this disease.2 Because AS is associated with periodontitis,3 those with AS have significantly higher risks of PD.4 Ankylosing spondylitis and PD are 2 similar diseases from many aspects. The cytokine profiles are almost the same,5 and both diseases are observed in soft and hard connective tissue.4

In 2009, the Assessment of SpondyloArthritis International Society (ASAS) proposed a new terminology for spondyloarthritides (SpA) which is based on the classification criteria that changed the perspective of AS.6,7 From now on, the axial form of SpA (AxSpA) is equal to the (early) nonradiographic-type (nr-axial SpA) and radiographic-type AS (according to the older modified New York criteria).8 The advantage of the new terminology is that it includes patients with earlier and less frequent disease and reflects the severity of the spectrum that is seen in the clinical practice.

Periodontal Disease and Oral Bacteria

The causes of PD are multifactorial in that several bacterial species are involved, interacting with host tissues and cells and leading to the release of many inflammatory mediators.1 This in turn leads to the destruction of tooth–supporting structures.1 These diseases are classified into several groups. Among them, gingival diseases affect gingival tissues with no loss of attachment, whereas periodontitis is accompanied by inflammation within the supporting tissues of the teeth, attachment loss, and bone loss. It is clinically characterized by symptoms such as bleeding gums, bad breath, gingival recession, tooth mobility, and migration. Porphyromonas gingivalis is a Gram-negative, obligate anaerobic, nonmotile bacterium.1

Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia are associated with the pathogenesis of chronic periodontitis.1 The “red complex” comprises bacteria that are considered to be periodontal pathogens1 and include these 3. The red complex secretes peptidylarginine deiminases.5 This review examines the association between oral bacteria and the etiology of AS.

Periodontal Pathogens and AS

Anti–P. gingivalis and anti–Prevotella intermedia antibody titers were higher in patients with SpA than in healthy people.9 Sulfasalazine is an effective antibiotic treatment for AS.10 When reviewing the literature, 8 randomized controlled studies that focused on sulfasalazine use were found10–12; however, long-term use results in drug resistance. It is more effective for the peripheral signs than the spinal symptoms of AS.17

In yet another study of 22 patients with active AS, a new treatment modality was evaluated and compared with an oral treatment.18 Rifamycin was found to be significantly effective in the treatment of AS.

In yet another study, researchers used moxifloxacin—a quinolone group antibiotic used to treat anaerobic bacteria—for...
AS treatment in 2007. In this open-label study, moxifloxacin was continuously effective in treating the symptoms and clinical parameters of AS.

The risk of AS in HLA-B27–positive individuals is 2% to 5%, and 90% to 95% of affected White individuals are HLA-B27 positive. Twenty-five subtypes of HLA-B27 have been assigned on the basis of nucleotide sequence homology; they encode 23 different products. The prevalence of these subtypes varies depending on ethnicity, and B*2705, followed by B*2702, is the most common subtype in Whites.

Determination of the crystal structure of HLA-A2705 and B27 has characterized the peptide binding properties of it and other subtypes suggest a mechanism for the B27 disease association. Most naturally bound peptides eluted from B27 share arginine at position 2 that interacts with the glutamine at position 45 in the B pocket. These observations suggest that the B pocket may convey specificity for the binding of putative arthritogenic peptide(s).

The polymorphic region of B27, spanning residues 169 to 179, demonstrates homology between bacterial proteins and one of the endogenous peptides presented in vivo by B27 in B27–transfected lymphoblastoid cell lines. Neither B27 transgenic rats nor B27 transgenic mice develop either intestinal inflammation or peripheral arthritis when maintained in germ-free environments. Furthermore, only transgenic rats colonized with defined bacterial cocktails that contain Bacteroides spp develop intestinal inflammation or peripheral arthritis when maintained in germ-free environments.

Conclusions

Periodontal pathogens are responsible for the development of AS in genetically susceptible individuals. This finding should guide the development of more comprehensive and efficacious treatment strategies for AS.

Author Contributions

MÖ wrote the manuscript. The author read and approved the final manuscript.

REFERENCES

1. Marshall PD, Martin MV, eds. Oral Microbiology. 4th ed. Bodmin, UK: MPG Books Ltd; 2001.
2. Maksymowych WP. Etiology and pathogenesis of ankylosing spondylitis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. Rheumatology, 3rd ed. Barcelona, Spain: Mosby; 2003:1183–1191.
3. Keller JJ, Kang JH, Lin HC. Association between ankylosing spondylitis and chronic periodontitis: a population-based study. Arthritis Rheum. 2013;65:167–173.
4. Piscon N, Piscon T, Gilmé E, et al. Periodontal disease in patients with ankylosing spondylitis. Ann Rheum Dis. 2010;69:34–38.
5. Sezer U, Erciyas K, Pehlivan Y, et al. Serum cytokine levels and periodontal parameters in ankylosing spondylitis. J Periodontal Res. 2012;47:396–401.
6. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777–783.
7. van der Horst-Bruinsma IE. Treatment of non-radiographic axial spondyloarthritis: it is only the beginning. Ann Rheum Dis. 2013;72:789–790.
8. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–386.
9. Rinaudo-Gaujous M, Moreau A, Blasco-Baque V, et al. Evaluation of porphyromonas gingivalis serology in rheumatic and non-rheumatic inflammatory disease [abstract]. Ann Rheum Dis. 2014;73:A73.
10. Dougados M, Boumier P, Amor B. Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. Br Med J (Clin Res Ed). 1986;293:911–914.
11. Nasilla M, Lehtinen K, Leirisalo-Repo M, Luukkainen R, Murru O, Yli-Kerttula U. Sulphasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum. 1988;31:1111–1116.
12. Davis MJ, Dawes PT, Beswick E, Lewin IV, Stanworth DR. Sulphasalazine therapy in ankylosing spondylitis: its effect on disease activity, immunoglobulin A and the complex immunoglobulin A-alpha-1-antitrypsin. Br J Rheumatol. 1989;28:410–413.
13. Corkill MM, Johanputra P, Gibson T, Macfarlane DG. A controlled trial of sulphasalazine treatment of chronic ankylosing spondylitis: failure to demonstrate a clinical effect. Br J Rheumatol. 1990;29:41–45.
14. Taylor HG, Beswick EJ, Dawes PT. Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment. Clin Rheumatol. 1991;10:43–48.
15. Kirwan J, Edwards A, Huifeldt B, Thompson P, Currey H. The course of established ankylosing spondylitis and the effects of sulphasalazine over 3 years. Br J Rheumatol. 1993;32:729–733.
16. Dougados M, van der Linden S, Leirisalo-Repo M, et al. Sulphasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 1995;38:618–627.
17. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulphasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1999;42:2325–2329.
18. Caruso I, Carzola M, Santandrea S. Clinical improvement in ankylosing spondylitis with rifamycin SV infiltrations of peripheral joints. J Int Med Res. 1992;20:171–181.
19. Ogorenek M. Treatment of ankylosing spondylitis with moxifloxacin. South Med J. 2007;100:366–370.